Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
You may also be interested in...
Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.
Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.
Singapore Biomedical Sciences Group Director Yeoh Keat Chuan: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Singapore government official talks about the country’s R&D strengths and how it is handling increased competition from other Asian nations.